Clinical Trials Logo

Clinical Trial Summary

This was a double-blind, placebo-controlled, parallel-design, 6-arm, fixed dose study. The study enrolled 135 adult male and female subjects with Stage 3 or 4 chronic kidney disease and low serum bicarbonate levels. The study was conducted in two parts. In Part 1 study drug dosing (TRC101 or placebo) continued for 14 days twice daily (BID). In Part 2 study drug dosing (TRC101 or placebo) continued for 14 days once daily (QD).

The maximum study duration per subject was anticipated to be up to 42 days.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02809183
Study type Interventional
Source Tricida, Inc.
Contact
Status Completed
Phase Phase 1/Phase 2
Start date March 2016
Completion date November 2016

See also
  Status Clinical Trial Phase
Completed NCT05669313 - The Effects of Hypothermia and Acidosis on Coagulation During Treatment With Rivaroxaban Measured With ROTEM
Recruiting NCT03309423 - Is Venous to Arterial Conversion (v-TAC) of Blood Gas Reliable in Critical Ill Patients in the ICU? N/A
Completed NCT02862925 - Introducing Fetal Scalp Stimulation as an Adjunct to Intermittent Auscultation in Low-Resource Settings. N/A
Completed NCT01119170 - Safety of D-lactate Producing Probiotics N/A
Completed NCT04231045 - The Impact of the pH on Cardiac Function in the Critically Ill Patient
Completed NCT03102996 - Preserve-Transplant Study Phase 4
Active, not recruiting NCT04459442 - Placental Transfusion in the 'Natural' Delivery: Effect of Early and Late Umbilical Cord Clamping N/A
Completed NCT01831492 - Effects of Zeolite + Dolomite on Performance and Acidosis N/A
Completed NCT00905502 - Intraoperative Fluid Management in Laparoscopic Bariatric Surgery N/A